

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/064830 A1

(51) International Patent Classification:

A61K 9/16 (2006.01) A61M 31/00 (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:

PCT/US2022/077999

(22) International Filing Date:

12 October 2022 (12.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/254,974	12 October 2021 (12.10.2021)	US
63/255,387	13 October 2021 (13.10.2021)	US
63/311,841	18 February 2022 (18.02.2022)	US

(71) Applicant: **TARIS BIOMEDICAL LLC** [US/US]; 113 Hartwell Avenue, Lexington, Massachusetts 02421 (US).

(72) Inventors: **MAMIDI, Srinivas**; 1000 Route 202, Raritan, New Jersey 08869 (US). **DANIEL, Karen**; 113 Hartwell Avenue, Lexington, Massachusetts 024021 (US). **GIESING, Dennis**; 4421 SW Gull Point Drive, Lee's Summit, Missouri 64082 (US). **HEYNS, Philip Erna H**; Turnhoutseweg 30, B-2340 Beerse (BE). **DHONDT, Jens Julien Maurits Andre**; Turnhoutseweg 30, B-2340 Beerse

(BE). **DELAET, Urbain Alfons C**; Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: **POON, Meghan** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) Title: ERDAFITINIB FORMULATIONS AND SYSTEMS FOR INTRAVESICAL ADMINISTRATION




FIG. 2

(57) Abstract: Provided herein are solid pharmaceutical compositions comprising erdafitinib, processes for making such formulations, and drug delivery systems comprising such formulations, including systems for intravesical administration.

[Continued on next page]

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*